Drug induced allergic glossitis – Report of a rare case

Here, we present the case of a 29-year-old woman with nasal septal perforation and positive myeloperoxidase- (MPO-) anti-neutrophil cytoplasmic antibody (ANCA). She had been diagnosed with Graves’ disease and had been treated with propylthiouracil (PTU) for 14 months. A biopsy of the nasal septum revealed an infiltration of inflammatory cells, with no evidence of malignancy or granulomatous change. Because of the use of PTU, destructive nasal lesion, and positive MPO-ANCA, she was diagnosed with drug-induced ANCA-associated vasculitis (AAV) and was treated with prednisolone and methotrexate after the cessation of PTU. Although PTU is known to be the medicine that induces drug-induced AAV, the manifestation of nasal septal perforation in drug-induced AAV is poorly identified. This is the rare case of drug-induced AAV which manifested only nasal septal perforation.

Download Full-text

A rare case of drug-induced hypersensitivity syndrome by pirfenidone for idiopathic pulmonary fibrosis

Allergology International ◽

10.1016/j.alit.2018.02.010 ◽

2018 ◽

Vol 67 (3) ◽

pp. 425-426 ◽

Cited By ~ 2

Author(s):

Kumiko Suda ◽

Koji Kamiya ◽

Binluen Chiang ◽

Hirofumi Okada ◽

Naoko Mato ◽

...

Keyword(s):

Idiopathic Pulmonary Fibrosis ◽

Pulmonary Fibrosis ◽

Rare Case ◽

Hypersensitivity Syndrome ◽

Drug Induced

Download Full-text

Drug Induced Liver Injury Caused by Herbal Male Enhancing products: A Rare Case

The American Journal of Gastroenterology ◽

10.14309/00000434-201610001-02013 ◽

2016 ◽

Vol 111 ◽

pp. S959-S960

Author(s):

Rooma Nankani ◽

Amruta Panwala ◽

Deepa Nankani ◽

Ameet Kumar ◽

Lisa Rossi

Keyword(s):

Liver Injury ◽

Rare Case ◽

Drug Induced ◽

Drug Induced Liver Injury

Download Full-text

Phenytoin-Induced Gingival Overgrowth with Predominant Involvement of Hard Palate and Floor of Oral Cavity: A Case Report and Review of Literature

Journal of Neurosciences in Rural Practice ◽

10.1055/s-0040-1709249 ◽

2020 ◽

Vol 11 (02) ◽

pp. 349-352

Author(s):

Rajeev Sharma ◽

Prasenjit Das ◽

Arvind Kairo ◽

Shashank S. Kale

Keyword(s):

Case Report ◽

Oral Cavity ◽

Rare Case ◽

Hard Palate ◽

Seizure Control ◽

English Literature ◽

Review Of Literature ◽

Drug Induced ◽

Gingival Overgrowth

AbstractDrug-induced gingival overgrowth (DIGO) secondary to chronic phenytoin intake for seizure control is a well-recognized phenomenon. Phenytoin-induced gingival overgrowth (PIGO) usually resolves gradually following cessation of phenytoin intake. It is usually seen throughout the dentate regions of the maxillary and mandibular dental arches, but more severely affect their anterior portions exposed to atmosphere. We report a rare case of PIGO predominantly involving hard palate and floor of oral cavity, which has not been reported in English literature till date.

Download Full-text

A Rare Case of Drug-Induced Erectile Dysfunction with Secukinumab Solved After Switch to Ixekizumab in A Psoriatic Patient: A Case Report

Current Drug Safety ◽

10.2174/1574886314666190726155147 ◽

2020 ◽

Vol 15 (1) ◽

pp. 69-72

Author(s):

Stefano Dastoli ◽

Luigi Francesco Iannone ◽

Luigi Bennardo ◽

Martina Silvestri ◽

Caterina Palleria ◽

...

Keyword(s):

Adverse Effect ◽

Erectile Dysfunction ◽

Sexual Dysfunction ◽

Rare Case ◽

Interleukin 17 ◽

Inflammatory Condition ◽

Biologic Drugs ◽

Drug Induced ◽

First Case ◽

First Time

Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic drugs inhibiting interleukin-17. Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug (ixekizumab). Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17. The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days. Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete skin clearance. Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and its resolution after the switch to another similar but different drug, highlighting the potential difference between anti-IL17A drugs.

Download Full-text